Delivery Order SPE2DB20D9331-SPE2DB24FL1S3
Award Date
9/5/24
Potential Completion Date
9/26/24
Potential Value
$9.3K
Federal Agency
Defense Logistics Agency
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a firm fixed-price delivery order under the Defense Logistics Agency's (DLA) SPE2DB Indefinite Delivery Contract (IDC) valued at $499,999,999. The contract covers a wide range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide. The current...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a delivery order under the Defense Logistics Agency's (DLA) SPE2DB program. The single-award indefinite delivery contract (IDC) has a ceiling value of up to $499,999,999 and runs through December 31, 2025. Under this contract, DMS Pharmaceutical Group provides a comprehensive range of pharmaceutical items, including both common medications and specialized drugs, to support the diverse medical supply...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, was issued by the Defense Logistics Agency (DLA) under the Medical Supply Chain division. The $9,671.25 firm fixed-price delivery order is for the pharmaceutical product XOLAIR 150 MG/ML SYRINGEML, with a completion date of June 4, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the DLA to issue delivery...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a delivery order valued at $98,132.40 issued by the Defense Logistics Agency (DLA) under the SPE2DB Indefinite Delivery Contract (IDC). The contract is for the delivery of XOLAIR 150 MG/ML SYRINGEML, a specialized pharmaceutical product. The IDC, valued at $499,999,999, enables the DLA to issue firm fixed-price delivery orders for a wide range of pharmaceutical items to support the medical supply needs...
This contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a delivery order valued at $74,275.20 issued under the Defense Logistics Agency's (DLA) SPE2DB Indefinite Delivery Contract. The contract is for the provision of pharmaceutical products, including Xolair 150 mg/1.2 ml powder, to support the medical supply needs of military healthcare facilities. This single-award IDC, valued at $499,999,999, enables the DLA to issue firm fixed-price...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) as a delivery order valued at $37,137.60. The contract provides for the delivery of Xolair 150 mg/mL syringes to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a delivery order under the Defense Logistics Agency's (DLA) SPE2DB program. The $18,612.48 firm fixed-price contract is for the delivery of the pharmaceutical product Xolair 150 mg/mL syringe to support the medical supply needs of Department of Defense (DoD) healthcare facilities. The contract has no set-aside designation and is part of DMS Pharmaceutical Group's broader indefinite delivery contract...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a firm fixed-price delivery order valued at $15,474.00. The contract was awarded by the Defense Logistics Agency (DLA) and has an ultimate completion date of September 18, 2024. DMS Pharmaceutical Group Inc. holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs through December 31, 2025. This...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, was issued by the Defense Logistics Agency (DLA) under the SPE2DB program. The $6,963.30 firm fixed-price delivery order is for the pharmaceutical product Xolair 150 mg/mL syringe. This award is part of DMS Pharmaceutical Group's larger $499,999,999 indefinite delivery contract (IDC) with the DLA to provide a wide range of pharmaceutical items, including both common and specialized medications, to support...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) under the SPE2DB program. The $4,642.20 firm fixed-price delivery order is for the provision of Xolair 150 mg/mL syringes, a specialized pharmaceutical product, with a period of performance through January 25, 2024. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA to supply a...